Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis

被引：2

作者：

Hannech, Emna ^{[1
,2
]}

Boussaid, Soumaya ^{[1
,2
]}

Rekik, Sonia ^{[1
,2
]}

Jemmali, Samia ^{[1
,2
]}

Ajlani, Houda ^{[1
]}

Cheour, Elhem ^{[1
,2
]}

Sahli, Hela ^{[1
,2
]}

Elleuch, Mohamed ^{[1
,2
]}

机构：

[1] La Rabta Hosp, Rheumatol Dept, Tunis, Tunisia

[2] Univ Tunis El Manar, Fac Med Tunis, Tunis, Tunisia

来源：

CLINICAL CASE REPORTS | 2021年 / 9卷 / 06期

关键词：

certolizumab pegol; rheumatoid arthritis; TNF inhibitor; tuberculosis; INFLIXIMAB; THERAPY; RISK;

D O I：

10.1002/ccr3.4307

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Tuberculosis must be considered in front of deterioration in general condition in patient with rheumatic disease under biological therapy. Rheumatologists may pay attention and screen infections before and after prescribing biological therapy.

引用

页数：3

共 8 条

[1] Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry [J].

Atzeni, Fabiola ;

Sarzi-Puttini, Piercarlo ;

Botsios, Costantino ;

Carletto, Antonio ;

Cipriani, Paola ;

Favalli, Ennio Giulio ;

Frati, Elena ;

Foschi, Valentina ;

Gasparini, Stefania ;

Giardina, AnnaRita ;

Gremese, Elisa ;

Iannone, Florenzo ;

Sebastiani, Marco ;

Ziglioli, Tamara ;

Biasi, Domenico ;

Ferri, Clodoveo ;

Galeazzi, Mauro ;

Gerli, Roberto ;

Giacomelli, Roberto ;

Gorla, Roberto ;

Govoni, Marcello ;

Lapadula, Giovanni ;

Marchesoni, Antonio ;

Salaffi, Fausto ;

Punzi, Leonardo ;

Triolo, Giovanni ;

Ferraccioli, Gianfranco .

AUTOIMMUNITY REVIEWS, 2012, 12 (02) :225-229

[2] Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis [J].

Doan, Tan N. ;

Eisen, Damon P. ;

Rose, Morgan T. ;

Slack, Andrew ;

Stearnes, Grace ;

McBryde, Emma S. .

PLOS ONE, 2017, 12 (11)

[3] Tuberculosis and Biologic Therapies Anti-Tumor Necrosis Factor-α and Beyond [J].

Godfrey, Mark S. ;

Friedman, Lloyd N. .

CLINICS IN CHEST MEDICINE, 2019, 40 (04) :721-+

[4] Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [J].

Keane, J ;

Gershon, S ;

Wise, RP ;

Mirabile-Levens, E ;

Kasznica, J ;

Schwieterman, WD ;

Siegel, JN ;

Braun, MM .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1098-1104

[5]

Liote H, 2008, REV MAL RESPIR, V25, P62

[6] Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region [J].

Wang, Xing ;

Wong, Sunny H. ;

Wang, Xian-Song ;

Tang, Whitney ;

Liu, Chang-Qin ;

Niamul, Gani ;

Wu, Bin ;

Tam, Lai-Shan ;

Wu, Justin C. Y. ;

Chan, Francis K. L. ;

Sung, Joseph J. Y. ;

Ng, Siew C. .

RHEUMATOLOGY, 2019, 58 (05) :803-810

[7] Risk of tuberculosis infection in anti-INF-α biological therapy: From bench to bedside [J].

Xie, Xi ;

Li, Fen ;

Chen, Jin-Wei ;

Wang, Jia .

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2014, 47 (04) :268-274

[8] Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials [J].

Zhang, Zheng ;

Fan, Wei ;

Yang, Gui ;

Xu, Zhigao ;

Wang, June ;

Cheng, Qingyuan ;

Yu, Mingxia .

BMJ OPEN, 2017, 7 (03)

← 1 →